ComplianceOnline

FDA Guidance on Postmarket Management of Cybersecurity in Medical Devices

  • By: Staff Editor
  • Date: February 15, 2017
  • Source: http://www.fda.gov/
Access Regulatory Compliance Training sessions led by expert panelists below.

Compliance Webinars | Virtual Seminars for Professionals

FDA Guidance on Postmarket Management of Cybersecurity in Medical Devices

The significant technological advancements in medical device in today’s world has laterally increased the risk of cybersecurity breaches that could affect device’s performance and functionality. Hence, medical device manufacturers are required to consider cybersecurity throughout the product lifecycle, including during the research and development, design, production, distribution, and maintenance of the device.

The US FDA recently issued the guidance that offers recommendations for handling postmarket cybersecurity vulnerabilities for the medical devices. This guidance is applicable to any marketed medical device including:

  • Devices that have software (including firmware) or programmable logic.
  • Software that is a medical device, including mobile medical applications.
  • Devices that are considered as a part of an interoperable system.
  • Legacy devices that is medical devices that are already on the market or in use.

Related Training:

Medical Device Software Risk Management, Cybersecurity and Assurance Case


Overview of Requirements

The guidance highlights that device manufacturers should monitor, identify, and address cybersecurity threats and exploits as part of their postmarket management activities of devices.

The key areas addressed in the guidance are:

  • General principles including premarket and postmarket considerations, maintaining safety and essential performance.
  • Medical device cybersecurity risk management program that focus on assessing exploitability of the cybersecurity vulnerability, measuring severity of patient harm and evaluation of risk of patient harm.
  • Remediating and reporting cybersecurity vulnerabilities including specific suggestions for managing controlled risks of patient harm and uncontrolled risk to safety and essential performance.
  • Recommended content to be included in premarket approval (PMA) periodic reports.
  • Criteria for defining active participation by a manufacturer in an Information Sharing Analysis Organizations (ISAO).

The guidance further clarifies elements of an effective postmarket cybersecurity program including identification, protection, and risk mitigation of safety and essential performance for improving critical infrastructure cybersecurity.

Click here to download the file

Trending Compliance Trainings

Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
GAMP Data Integrity 21 CFR Part 11 Training Course
By - Kelly Thomas
On Demand Access Anytime
NEW Reclamation Process - Fed Gov't Payments
By - Donna K Olheiser
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
How to conduct an effective BSA Audit
By - Justin Muscolino
On Demand Access Anytime
Installation and Qualification of the Packaging Lines
By - John E Lincoln
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading